Population pharmacokinetics of artemether–lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria
British Journal of Clinical Pharmacology · 2026-02 · 92 (2) · 589-605
DOI: 10.1002/bcp.70301 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 06.10.2025. Verfasst von Junjie Ding und 24 weiteren Autor:innen. Beteiligte Einrichtung: Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Amodiaquine, Antimalarials, Artemether, Lumefantrine Drug Combination, Malaria, Falciparum. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
Aims
Resistance to the artemisinins and the artemisinin‐based combination therapy (ACT) partner drugs has developed in Southeast Asia, and artemisinin resistance has also emerged in eastern Africa. Triple ACTs (triple artemisinin‐based combination therapies, TACT), consisting of two partner drugs with different mechanisms of action and similar pharmacokinetic profiles, combined with an artemisinin derivative can help to delay or prevent artemisinin resistance and prolong the useful lifetime of the partner drugs. This study aims to characterize the pharmacokinetic properties of a recommended TACT, artemether‐lumefantrine plus amodiaquine, using data from two large clinical trials.
Methods
We analysed data from two randomized, controlled intervention trials conducted between 2015 and 2020 in one African country and two Southeast Asian countries, in which artemether‐lumefantrine was administered alone ( n = 443) or together with amodiaquine ( n = 442) to patients with uncomplicated P . falciparum malaria. Both studies included a sub‐cohort with dense pharmacokinetic sampling, combined with sparse data in the other patients. Concentration–time data of artemether, dihydroartemisinin, lumefantrine, desbutyllumefantrine, amodiaquine and desethylamodiaquine were analysed using nonlinear mixed‐effects modelling.
Results
Pharmacokinetic models were developed for all drugs and demonstrated good predictive performance and goodness‐of‐fit diagnostics. Coadministered amodiaquine was not a significant covariate on pharmacokinetic properties of artemether‐lumefantrine. Model‐predicted C max and AUC (median [95% confidence interval, CI]) for artemether were 256 (159–407) ng/mL and 2850 (1820‐4920) h·ng/mL for artemether‐lumefantrine alone, and 230 (123–391) ng/mL and 2800 (1570‐4570) h·ng/mL for artemether‐lumefantrine‐amodiaquine. For dihydroartemisinin, values were 135 (54.5–214) ng/mL and 1870 (813–3015) h·ng/mL for artemether‐lumefantrine alone, and 116 (40.8–186) ng/mL and 1580 (547–2680) h·ng/mL for artemether‐lumefantrine‐amodiaquine. For lumefantrine, values were 15.2 (2.90–31.3) μg/mL and 600 (275–1230) h·μg/mL for artemether‐lumefantrine alone, and 14.1 (2.72–31.4) μg/mL and 586 (269–1070) h·μg/mL for artemether‐lumefantrine‐amodiaquine. Day 7 concentrations of lumefantrine were 452 (215–1240) and 438 (204–1030) μg/mL for artemether‐lumefantrine alone and artemether‐lumefantrine‐amodiaquine, respectively. All geometric mean ratios (GMRs) for the drug–drug interaction (DDI) effect on key pharmacokinetic parameters of artemether, dihydroartemisinin and lumefantrine fell within the 0.80–1.25 range, with the majority of the corresponding 90% CI also contained within this range. This indicates no clinically relevant DDIs between artemether‐lumefantrine and amodiaquine.
Conclusions
The DDI effect of amodiaquine on the pharmacokinetics of artemether‐lumefantrine is expected to be minimal, the based on the current analysis. However, further large‐scale clinical trials are needed to confirm this finding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
- Hospital for Tropical Diseases, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
- Infectious Diseases Data Observatory, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
- National Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia.
- Kinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
ORCID-Profile: Junjie Ding, Richard M Hoglund, Rob W van der Pluijm, James J Callery, Thomas J Peto, Rupam Tripura, Sukanta Das, Nguyễn Hoàng Châu, Mavuto Mukaka, Caterina Fanello, Marie A Onyamboko, Anupkumar R Anvikar, Mayfong Mayxay, Frank Smithuis, Lorenz von Seidlein, Mehul Dhorda, Ho Dang Trung Nghia, Nicholas J White, Arjen M Dondorp, Joel Tarning
Förderung
- Wellcome Trust
- Bill and Melinda Gates Foundation
Zitieren
APA
Ding, J., Hoglund, R. M., van der Pluijm, R. W., Callery, J. J., Peto, T. J., Tripura, R., Das, S., Châu, N. H., Promnarate, C., Mukaka, M., Dysoley, L., Fanello, C., Onyamboko, M. A., Anvikar, A. R., Mayxay, M., Smithuis, F., von Seidlein, L., Dhorda, M., Amaratunga, C., …, & Tarning, J. (2026). Population pharmacokinetics of artemether–lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria. British Journal of Clinical Pharmacology, 92(2), 589-605. https://doi.org/10.1002/bcp.70301
Vancouver
Ding J, Hoglund RM, van der Pluijm RW, Callery JJ, Peto TJ, Tripura R, et al. Population pharmacokinetics of artemether–lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria. British Journal of Clinical Pharmacology. 2026;92(2):589-605. doi:10.1002/bcp.70301
BibTeX
@article{Ding2026,
author = {Ding, Junjie and Hoglund, Richard M and van der Pluijm, Rob W and Callery, James J and Peto, Thomas J and Tripura, Rupam and Das, Sukanta and Châu, Nguyễn Hoàng and Promnarate, Cholrawee and Mukaka, Mavuto and Dysoley, Lek and Fanello, Caterina and Onyamboko, Marie A and Anvikar, Anupkumar R and Mayxay, Mayfong and Smithuis, Frank and von Seidlein, Lorenz and Dhorda, Mehul and Amaratunga, Chanaki and Faiz, M Abul and Nghia, Ho Dang Trung and White, Nicholas J and Day, Nicholas P J and Dondorp, Arjen M and Tarning, Joel},
title = {Population pharmacokinetics of artemether–lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
volume = {92},
number = {2},
pages = {589--605},
doi = {10.1002/bcp.70301}
}
EUVIMED